Vesper Bio announces completion of single ascending dose stage in trial of its lead candidate VES001, a potentially disease-modifying treatment for fronto-temporal dementia

Vesper Bio United Kingdom United States of America Denmark

View original content:https://www.prnewswire.co.uk/news-releases/vesper-bio-announces-completion-of-single-ascending-dose-stage-in-trial-of-its-lead-candidate-ves001-a-potentially-disease-modifying-treatment-for-fronto-temporal-dementia-302158344.html